On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company's history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone was confident, but the numbers underneath told a more complicated story about what launching a first drug really costs.
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
20 hours ago
